A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
Conditions: Cardiovascular Interventions: Drug: AZD1705; Other: Placebo Sponsors: AstraZeneca; Parexel Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
Conditions: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: Hospital Israelita Albert Einstein; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
Conditions: EGPA - Eosinophilic Granulomatosis With Polyangiitis Interventions: Drug: Tezepelumab; Drug: Placebo Sponsors: Imperial College London; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Brazilian Reality of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma; Hepatocellular Carcinoma by BCLC Stage; Hepatocellular Carcinoma Stage I; Hepatocellular Carcinoma Stage II; Hepatocellular Carcinoma Stage III Sponsors: Hospital Israelita Albert Einstein; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Conditions: Gastric Cancer; Gastroesophageal Junction Cancer; Pancreatic Adenocarcinoma Interventions: Drug: AZD0901; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: l-leucovorin; Drug: Irinotecan; Drug: Nanoliposomal Irinotecan; Drug: Gemcitabine Sponsors: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
Conditions: Cardiovascular Interventions: Drug: AZD1705; Other: Placebo Sponsors: AstraZeneca; Parexel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Acalabrutinib Real World Italian obSErvational Study -ARISE
Conditions: Chronic Lymphocytic Leukemia Interventions: Drug: acalabrutinib Sponsors: AstraZeneca; Yghea Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
Conditions: Chronic Kidney Disease (CKD) Sponsors: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
The Effect of Asthma Flare-up Clinic After Exacerbation
Conditions: Asthma; Asthma Attack Interventions: Other: Follow-up in a flare-up clinic Sponsors: Tel-Aviv Sourasky Medical Center; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
Conditions: Healthy Participants Interventions: Drug: Baxdrostat; Drug: Placebo; Drug: Moxifloxacin Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
LTFU for All Cell and Gene Therapy Studies
Conditions: Hepatocellular Carcinoma; Prostate Cancer Interventions: Biological: AZD5851 Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Conditions: Transthyretin Amyloid Cardiomyopathy Interventions: Drug: Eplontersen; Drug: Placebo Sponsors: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Conditions: Lung Cancer Interventions: Drug: Osimertinib; Drug: Cisplatin or Carboplatin; Pemetrexed or Paclitaxel; Drug: Radiation Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
Conditions: Non-Small Cell Lung Cancer Interventions: Other: None (Observational Study) Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Conditions: ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) Interventions: Drug: AZD8421; Drug: Camizestrant; Drug: Ribociclib; Drug: Palbociclib; Drug: Abemaciclib Sponsors: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials
